Current Topics in Intermediate and Intensive Care

23rd June 2015 – PORTO, PORTUGAL

Centro Hospitalar do Porto – Hospital Sto António

Acute on Chronic Liver Failure

Monothematic conference

Hosts and Chairman’s: Helena P Miranda, Porto, and Richard Moreau, Paris

7:30 – Registry

8:30 – Opening ceremony

**8:40 – Where it all begins: the CANONIC Study**

8:40 – Main fundamentals: acute decompensation vs old and new definition(s) of ACLF. (Vicente Arroyo, Barcelona)

9:00 – SOFA vs CLIF-SOFA vs MELD: which score is the best to predict the outcome. (François Durand, Paris)

9:20 – Why is systemic inflammation related to ACLF? Back to the basics. (Thierry Gustot, Brussels)

9:40 – Clinical Case and discussion (Diana Valadares, Porto)

**10:00 – Infection and ACLF**

10:00 – Gut microbiota and bacterial translocation in cirrhosis: which biomarkers may be used and consequences to be expected. (Reiner Wiest, Bern)

10:20 – Antibiotics and cirrhosis complications prevention. Where do we stand? (Laure Elkrief, Geneva)

10:40 – Is ACLF a risk factor for fungal infections? When to prevent, how to treat. (Faouzi Saliba, Paris)

11:00 – Clinical Case and discussion (Pedro Vita, Porto)
11:20 – Coffee-break

12:00 – Alcohol and ACLF

12:00 – The burden of alcohol consumption in Europe. Local and European strategies to lower consumption. (Helena Cortez-Pinto, Lisboa)

12:20 – Medical treatment for acute alcoholic hepatitis: where do we stand? (Julia Wendon, London)

12:40 – Liver transplantation as the last stronghold for acute alcoholic hepatitis? (Philippe Mathurin, Lille)

13:00 – Clinical Case and discussion (Arlindo Guimas, Porto)

13:20 – Lunch

14:20 – Factors associated/inducing decompensation in cirrhosis

14:20 – Hepatic encephalopathy and its role in acute decompensation, ACLF and prognosis: why the differences? (Manuel Romero-Gómez, Seville)

14:40 – Portal vein thrombosis and cirrhosis decompensation: is there really a cause-effect relationship? (Filipe Nery, Porto)

15:00 – TIPS in cirrhosis: state of play! (Arnulf Ferlitsch, Vienna)

15:20 – Clinical Case and discussion (Sofia Ferreira, Porto)

15:40 – Special treatments for special patients

15:40 – Albumin use in specific settings in cirrhosis: shall we rationalize or generalize? (Rajiv Jalan, London)

16:00 – May new DAAs avoid LT in listed HCV patients with decompensated cirrhosis? (Marina Berenguer, Valencia)

16:20 – Is ACLF a motif to prioritize or temporary contraindicate patients in list for LT? (Luis Tomé, Coimbra)

16:40 – Clinical Case and discussion (Teresa Moreira, Porto)

17:00 – Closing ceremony and Porto d’Honra